A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L, Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F, Heidel F, Heuser M.
Shahswar R, et al. Among authors: voss a.
Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501-6. Online ahead of print.
Leukemia. 2025.
PMID: 39779979